肝硬化腹水治疗的新进展

陈煜; 周莉

doi:10.3969/j.issn.1001-5256.2016.06.009

肝硬化腹水治疗的新进展

DOI: 10.3969/j.issn.1001-5256.2016.06.009

陈煜,
周莉

首都医科大学附属北京佑安医院人工肝中心

基金项目:

北京卫生系统高技术人才培养项目基金(2013-3-071)；北京市医院管理局临床医学发展专项基金资助项目(No.XM201308);北京市医院管理局“登峰”人才培养计划基金资助项目(No.DFL20151601)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2416
- HTML全文浏览量: 10
- PDF下载量: 635
- 被引次数: 0
出版历程
- 收稿日期: 2016-03-09
- 出版日期: 2016-06-20

Research advances in treatment of cirrhotic ascites

Chen Yu,
Zhou Li

Artificial Liver Treatment & Training Center,Beijing You An Hospital,Capital Medical University

Research funding:

摘要

摘要: 腹水是肝硬化最常见并发症之一,预防和控制腹水的发生和发展是改善肝硬化患者预后的关键。就近几年腹水治疗的新进展进行总结与讨论,主要包括病因治疗、限钠摄入、利尿剂治疗等一线治疗方法的更新,以及对于顽固性腹水治疗的新探索。
- 肝硬化 /
- 腹水 /
- 治疗
Abstract: Ascites is the most common complication of liver cirrhosis,and prevention and control of the development and progression of ascites are the key to improving the prognosis of patients with liver cirrhosis.This article summarizes the new advances in the treatment of ascites,including the update on first- line therapeutic methods such as etiological treatment,limited intake of sodium,and diuretic treatment,and investigates the treatment of intractable ascites.
- liver cirrhosis /
- ascites /
- therapy

HTML全文

参考文献(45)

[1]RUNYON BA,AASLD.Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012[J].Hepatology,2013,57(4):1651-1653.

[2]PLANAS R,MONTOLIU S,BALLESTE B,et al.Natural history of patients hospitalized for management of cirrhotic ascites[J].Clin Gastroenterol Hepatol,2006,4(11):1385-1394.

[3]HONDA K,SEIKE M,MURAKAMI K.Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis[J].World J Hepatol,2015,7(22):2404-2410.

[4]KIM MS,ONG M,QU X.Optimal management for alcoholic liver disease:conventional medications,natural therapy or combination?[J].World J Gastroenterol,2016,22(1):8-23.

[5]BIECKER E.Diagnosis and therapy of ascites in liver cirrhosis[J].World J Gastroenterol,2011,17(10):1237-1248.

[6]SOLE,SOLC,GINS P.Management of uninfected and infected ascites in cirrhosis[J].Liver Int,2016,36(Suppl 1):109-115.

[7] LENZ K,BUDER R,KAPUN L,et al.Treatment and management of ascites and hepatorenal syndrome:an update[J].Therap Adv Gastroenterol,2015,8(2):83-100.

[8] European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis[J].J Hepatol,2010,53(3):397-417.

[9] PEREZ-AYUSO RM,ARROYO V,PLANAS R,et al.Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites.Relationship between the diuretic response and the activity of the renin-aldosterone system[J].Gastroenterology,1983,84(5 Pt 1):961-968.

[10] BERNARDI M,SERVADEI D,TREVISANI F,et al.Importance of plasma aldosterone concentration on the natriuretic effect of spironolactone in patients with liver cirrhosis and ascites[J].Digestion,1985,31(4):189-193.

[11] ANGELI P,FASOLATO S,MAZZA E,et al.Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis:results of an open randomised clinical trial[J].Gut,2010,59(1):98-104.

[12] ANGELI P,WONG F,WATSON H,et al.Hyponatremia in cirrhosis:results of a patient population survey[J].Hepatology,2006,44(6):1535-1542.

[13]ALESSANDRIA C,ELIA C,MEZZABOTTA L,et al.Prevention of paracentesis-induced circulatory dysfunction in cirrhosis:standard vs half albumin doses.A prospective,randomized,unblinded pilot study[J].Dig Liver Dis,2011,43(11):881-886.

[14]MANDORFER M,BOTA S,SCHWABL P,et al.Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis[J].Gastroenterology,2014,146(7):1680-1690.

[15] LEITHEAD JA,RAJORIYA N,TEHAMI N,et al.Non-selective beta-blockers are associated with improved survival in patients with ascites listed for liver transplantation[J].Gut,2015,64(7):1111-1119.

[16] KRAG A,MADSEN BS.To block,or not to block in advanced cirrhosis and ascites:that is the question[J].Gut,2015,64(7):1015-1017.

[17]GUO TT,YANG Y,SONG Y,et al.Effects of midodrine in patients with ascites due to cirrhosis:systematic review and meta-analysis[J].J Dig Dis,2016,17(1):11-19.

[18]BARI K,MINANO C,SHEA M,et al.The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis[J].Clin Gastroenterol Hepatol,2012,10(10):1169-1175.

[19]BELLOT P,WELKER MW,SORIANO G,et al.Automated low flow pump system for the treatment of refractory ascites:a multicenter safety and efficacy study[J].J Hepatol,2013,58(5):922-927.

[20] THOMAS MN,SAUTER GH,GERBES AL,et al.Automated low flow pump system for the treatment of refractory ascites:a singlecenter experience[J].Langenbecks Arch Surg,2015,400(8):979-983.

[21]PONZIANI FR.Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications[J].World J Gastroenterol,2015,21(43):12322.

[22] ASSEM M,ELSABAAWY M,ABDELRASHED M,et al.Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites:a prospective randomized open-label comparative multicenter study[J].Hepatol Int,2016,10(2):377-385.

[23] Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,Chinese Medical Association;Severe Liver Diseases and Artificial Liver Group,Chinese Society of Hepatology,Chinese Medical Association.Guidelines for diagnosis and treatment liver failure[J].Chin J Clin Infect Dis,2012,5(6):321-327.(in Chinese)中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2012年版)[J].中华临床感染病杂志,2012,5(6):321-327.

[24]SOLA E,GINES P.Renal and circulatory dysfunction in cirrhosis:current management and future perspectives[J].J Hepatol,2010,53(6):1135-1145.

[25] WONG F.Recent advances in our understanding of hepatorenal syndrome[J].Nat Rev Gastroenterol Hepatol,2012,9(7):382-391.

[26]SERSTE T,GUSTOT T,RAUTOU PE,et al.Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites[J].J Hepatol,2012,57(2):274-280.

[27] STOCKAND JD.Vasopressin regulation of renal sodium excretion[J].Kidney Int,2010,78(9):849-856.

[28] YAMAMURA Y,NAKAMURA S,ITOH S,et al.OPC-41061,a highly potent human vasopressin V2-receptor antagonist:pharmacological profile and aquaretic effect by single and multiple oral dosing in rats[J].J Pharmacol Exp Ther,1998,287(3):860-867.

[29]SAKAIDA I,KAWAZOE S,KAJIMURA K,et al.Tolvaptan for improvement of hepatic edema:a phase 3,multicenter,randomized,double-blind,placebo-controlled trial[J].Hepatol Res,2014,44(1):73-82.

[30] IMAMURA T,KINUGAWA K,MINATSUKI S,et al.Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels[J].Int Heart J,2014(14):131-137.

[31] SAKAIDA I,NAKAJIMA K,OKITA K,et al.Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis?A post hoc analysis of previous clinical trials in Japan[J].J Gastroenterol,2015,50(10):1047-1053.

[32] SHOAF SE,BRICMONT P,MALLIKAARJUN S.Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function[J].Kidney Int,2014,85(4):953-961.

[33]GOLDSMITH SR,BART BA,BURNETT J.Decongestive therapy and renal function in acute heart failure:time for a new approach?[J].Circ Heart Fail,2014,7(3):531-535.

[34] VADUGANATHAN M,GHEORGHIADE M,PANG PS,et al.Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment[J].J Cardiovasc Med(Hagerstown),2012,13(7):415-422.

[35]UDELSON JE,ORLANDI C,OUYANG J,et al.Acute hemodynamic effects of tolvaptan,a vasopressin V2 receptor blocker,in patients with symptomatic heart failure and systolic dysfunction:an international,multicenter,randomized,placebo-controlled trial[J].J Am Coll Cardiol,2008,52(19):1540-1545.

[36]CARDENAS A,GINES P,MAROTTA P,et al.Tolvaptan,an oral vasopressin antagonist,in the treatment of hyponatremia in cirrhosis[J].J Hepatol,2012,56(3):571-578.

[37]AHLUWALIA V,HEUMAN DM,FELDMAN G,et al.Correction of hyponatremia improves cognition,quality of life,and brain edema in cirrhosis[J].J Hepatol,2015,1(62):75-82.

[38] KOGISO T,TOKUSHIGE K,HASHIMOTO E,et al.Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis[J].Hepatol Res,2016,46(3):e194-e200.

[39]ZHANG X,WANG SZ,ZHENG JF,et al.Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients[J].World J Gastroenterol,2014,20(32):11400-11405.

[40]OHKI T,SATO K,YAMADA T,et al.Efficacy of tolvaptan in patients with refractory ascites in a clinical setting[J].World J Hepatol,2015,7(12):1685-1693.

[41] TORRES VE,CHAPMAN AB,DEVUYST O,et al.Tolvaptan in patients with autosomal dominant polycystic kidney disease[J].NEngl J Med,2012,367(25):2407-2418.

[42] WATKINS PB,LEWIS JH,KAPLOWITZ N,et al.Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease:analysis of clinical trials database[J].Drug Saf,2015,38(11):1103-1113.

[43] YAN L,XIE F,LU J,et al.The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites:a meta-analysis of randomized controlled trials[J].BMC Gastroenterol,2015,15:65.

[44]PERICLEOUS M,SARNOWSKI A,MOORE A,et al.The clinical management of abdominal ascites,spontaneous bacterial peritonitis and hepatorenal syndrome:a review of current guidelines and recommendations[J].Eur J Gastroenterol Hepatol,2016,28(3):e10-e18.

[45] WONG F,WATSON H,GERBES A,et al.Satavaptan for the management of ascites in cirrhosis:efficacy and safety across the spectrum of ascites severity[J].Gut,2012,61(1):108-116.

施引文献

资源附件(0)

访问统计